Selatinib is a potent oral tyrosine kinase inhibitor that targets KIT and PDGFR, functioning as an anti-cancer agent primarily investigated for the treatment of gastrointestinal stromal tumors and other… Read more
Selatinib is a potent oral tyrosine kinase inhibitor that targets KIT and PDGFR, functioning as an anti-cancer agent primarily investigated for the treatment of gastrointestinal stromal tumors and other solid tumors dependent on these receptor pathways. Because the manufacturing and storage of this drug substance can lead to the formation of degradation products, access to high-quality reference standards is essential for rigorous analytical testing and quality control. This category includes Selatinib and its associated impurities, such as N-nitroso Selatinib, which are critical for impurity profiling and method validation. Laboratories utilize these compounds to accurately detect, identify, and quantify potential contaminants, ensuring compliance with strict regulatory standards for drug safety and stability throughout the pharmaceutical development lifecycle.